Education
About Us
Working with TipRanks
Follow Us
Formycon AG (DE:FYB)
XETRA:FYB
FYB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€19.18 - €64.40
Previous CloseN/A
Volume3.47K
Average Volume (3M)27.00K
Market Cap
€484.01M
Enterprise ValueN/A
Total Cash (Recent Filing)€40.63M
Total Debt (Recent Filing)€10.86M
Price to Earnings (P/E)5.9
Beta1.00
Next Earnings
Aug 13, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding17,664,427
10 Day Avg. Volume30,983
30 Day Avg. Volume26,998
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-11.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€44.83Price Target Upside63.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Formycon AG News
Bulls Say, Bears Say
Bulls Say
Cost ManagementThe decision to terminate the Phase 3 Lotus trial of FYB206 is expected to save investment costs in the high double-digit million range, showcasing Formycon’s expertise in biosimilar development.
Market PositionThe U.S. FDA has provisionally determined that Otulfi would be interchangeable with the reference drug Stelara, which is a positive development for market penetration.
Regulatory ApprovalThe U.S. FDA has confirmed that the ongoing Phase 1 Dahlia trial combined with a comprehensive analytical program would be sufficient to demonstrate the therapeutic comparability of FYB206 with Keytruda, thus eliminating the need for a Phase 3 trial.
Bears Say
Financial ExpectationsThe estimated market value of the firm has decreased to approximately $1.19B, leading to a lowered 12-month price target of €57 from €98 per share.
Market ChallengesSandoz has decided to temporarily suspend marketing activities in the U.S. due to ongoing price erosion and plans to reposition FYB201 in the U.S. after one year.
Revenue PerformanceTotal revenue was €5.3M, missing our projection of €14.0M.
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.28% Public Companies and
Individual Investors
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Formycon AG lowest stock price was €19.18 and its highest was €64.40 in the past 12 months.
What is Formycon AG’s market cap?
Formycon AG’s market cap is €484.01M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Aug 13, 2025 which is in 66 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on May 12, 2025. The company reported -€0.85 earnings per share for the quarter, missing the consensus estimate of €0.02 by -€0.87.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate is -0.08.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,664,427 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -€0.85 in its last earnings report, missing expectations of €0.02. Following the earnings report the stock price went down -0.205%.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in DE:FYB
Formycon AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€44.83 (63.61% Upside)
€44.83 (63.61% Upside)
Insider Transactions
Bought Shares
Worth €4.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.03%
12-Months-Change
Fundamentals
Return on Equity
-26.06%
Trailing 12-Months
Asset Growth
-13.33%
Trailing 12-Months
Company Description
Formycon AG
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
FYB Stock 12 Month Forecast
Average Price Target
€44.83
▲(63.61%Upside)
Technical Analysis
BB Biotech
―
Biotest
―
Evotec
―
Fresenius Medical Care AG & Co. KGaA
―
Porsche Automobil Holding
―